Perdagangan GlaxoSmithKline PLC - GSKl CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
Spread | 0.040 | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.028007% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | -0.015829% | ||||||||
Waktu biaya inap | 22:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 0.1 | ||||||||
Mata uang | GBP | ||||||||
Margin | 20% | ||||||||
Bursa efek | United Kingdom of Great Britain and Northern Ireland | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
GSK plc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Key Stats
Prev. Close* | 14.565 |
Open* | 14.66 |
1-Year Change* | -10.28% |
Day's Range* | 14.66 - 14.94 |
52 wk Range | 12.81-18.43 |
Average Volume (10 days) | 13.47M |
Average Volume (3 months) | 176.07M |
Market Cap | 60.83B |
P/E Ratio | 13.60 |
Shares Outstanding | 4.09B |
Revenue | 29.32B |
EPS | 1.09 |
Dividend (Yield %) | 6.05816 |
Beta | 0.57 |
Next Earnings Date | Apr 26, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 7, 2023 | 14.835 | 0.245 | 1.68% | 14.590 | 14.945 | 14.580 |
Feb 6, 2023 | 14.565 | 0.280 | 1.96% | 14.285 | 14.660 | 14.240 |
Feb 3, 2023 | 14.390 | 0.255 | 1.80% | 14.135 | 14.495 | 14.135 |
Feb 2, 2023 | 14.310 | 0.080 | 0.56% | 14.230 | 14.355 | 14.055 |
Feb 1, 2023 | 14.190 | -0.130 | -0.91% | 14.320 | 14.430 | 14.030 |
Jan 31, 2023 | 14.270 | 0.145 | 1.03% | 14.125 | 14.330 | 14.055 |
Jan 30, 2023 | 14.130 | 0.145 | 1.04% | 13.985 | 14.260 | 13.985 |
Jan 27, 2023 | 14.100 | 0.065 | 0.46% | 14.035 | 14.215 | 14.035 |
Jan 26, 2023 | 14.025 | 0.040 | 0.29% | 13.985 | 14.140 | 13.980 |
Jan 25, 2023 | 13.995 | 0.040 | 0.29% | 13.955 | 14.040 | 13.920 |
Jan 24, 2023 | 13.930 | -0.150 | -1.07% | 14.080 | 14.125 | 13.835 |
Jan 23, 2023 | 14.120 | 0.075 | 0.53% | 14.045 | 14.170 | 14.040 |
Jan 20, 2023 | 14.035 | -0.160 | -1.13% | 14.195 | 14.195 | 14.005 |
Jan 19, 2023 | 14.165 | 0.095 | 0.68% | 14.070 | 14.215 | 14.025 |
Jan 18, 2023 | 14.130 | -0.155 | -1.09% | 14.285 | 14.290 | 14.015 |
Jan 17, 2023 | 14.375 | 0.010 | 0.07% | 14.365 | 14.400 | 14.275 |
Jan 16, 2023 | 14.375 | 0.150 | 1.05% | 14.225 | 14.400 | 14.225 |
Jan 13, 2023 | 14.365 | 0.270 | 1.92% | 14.095 | 14.415 | 14.095 |
Jan 12, 2023 | 14.325 | 0.205 | 1.45% | 14.120 | 14.330 | 14.090 |
Jan 11, 2023 | 14.095 | 0.010 | 0.07% | 14.085 | 14.245 | 14.065 |
GlaxoSmithKline PLC Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 27889 | 30186 | 30821 | 33754 | 34099 | 34114 |
Revenue | 27889 | 30186 | 30821 | 33754 | 34099 | 34114 |
Cost of Revenue, Total | 8898 | 9317 | 9572 | 10168 | 10890 | 11427 |
Gross Profit | 18991 | 20869 | 21249 | 23586 | 23209 | 22687 |
Total Operating Expense | 25291 | 26005 | 25335 | 26793 | 26316 | 27949 |
Selling/General/Admin. Expenses, Total | 8859 | 9341 | 9408 | 10671 | 10717 | 10225 |
Research & Development | 3468 | 3862 | 3726 | 4338 | 4603 | 4776 |
Depreciation / Amortization | 41 | 45 | 44 | 64 | 76 | 101 |
Interest Expense (Income) - Net Operating | 3664 | 2139 | 1839 | -128 | 1220 | 1073 |
Unusual Expense (Income) | 782 | 1666 | 1038 | 2051 | -807 | 772 |
Other Operating Expenses, Total | -421 | -365 | -292 | -371 | -383 | -425 |
Operating Income | 2598 | 4181 | 5486 | 6961 | 7783 | 6165 |
Interest Income (Expense), Net Non-Operating | -628 | -646 | -602 | -708 | -432 | -1317 |
Other, Net | -31 | -10 | -84 | -32 | -383 | 594 |
Net Income Before Taxes | 1939 | 3525 | 4800 | 6221 | 6968 | 5442 |
Net Income After Taxes | 1062 | 3247 | 3921 | 5268 | 6388 | 5096 |
Minority Interest | -150 | -637 | -423 | -623 | -639 | -711 |
Net Income Before Extra. Items | 912 | 2610 | 3498 | 4645 | 5749 | 4385 |
Net Income | 912 | 1532 | 3623 | 4645 | 5749 | 4385 |
Income Available to Common Excl. Extra. Items | 912 | 2610 | 3498 | 4645 | 5749 | 4385 |
Income Available to Common Incl. Extra. Items | 912 | 1532 | 3623 | 4645 | 5749 | 4385 |
Dilution Adjustment | 1.074 | 0 | ||||
Diluted Net Income | 913.074 | 1532 | 3623 | 4645 | 5749 | 4385 |
Diluted Weighted Average Shares | 4909 | 4941 | 4971 | 5016 | 5038 | 5065 |
Diluted EPS Excluding Extraordinary Items | 0.186 | 0.52823 | 0.70368 | 0.92604 | 1.14113 | 0.86575 |
Dividends per Share - Common Stock Primary Issue | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
Diluted Normalized EPS | 0.32758 | 0.94697 | 0.85456 | 1.35566 | 0.9736 | 0.87285 |
Total Extraordinary Items | -1078 | 125 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 7418 | 8092 | 9077 | 9527 | 9780 |
Revenue | 7418 | 8092 | 9077 | 9527 | 9780 |
Cost of Revenue, Total | 2411 | 2519 | 2822 | 3675 | 3645 |
Gross Profit | 5007 | 5573 | 6255 | 5852 | 6135 |
Total Operating Expense | 5725 | 6453 | 7139 | 8632 | 6979 |
Selling/General/Admin. Expenses, Total | 2315 | 2498 | 2504 | 2908 | 2681 |
Research & Development | 1077 | 1165 | 1169 | 1363 | 1154 |
Depreciation / Amortization | 26 | 25 | 25 | 25 | 23 |
Unusual Expense (Income) | -13 | 323 | 735 | 796 | -385 |
Other Operating Expenses, Total | -91 | -77 | -116 | -135 | -139 |
Operating Income | 1693 | 1639 | 1938 | 895 | 2801 |
Interest Income (Expense), Net Non-Operating | -175 | -169 | -190 | -189 | -203 |
Net Income Before Taxes | 1518 | 1470 | 1748 | 706 | 2598 |
Net Income After Taxes | 1260 | 1538 | 1368 | 930 | 2167 |
Minority Interest | -187 | -143 | -200 | -181 | -365 |
Net Income Before Extra. Items | 1073 | 1395 | 1168 | 749 | 1802 |
Net Income | 1073 | 1395 | 1168 | 749 | 1802 |
Income Available to Common Excl. Extra. Items | 1073 | 1395 | 1168 | 749 | 1802 |
Income Available to Common Incl. Extra. Items | 1073 | 1395 | 1168 | 749 | 1802 |
Dilution Adjustment | 0 | ||||
Diluted Net Income | 1073 | 1395 | 1168 | 749 | 1802 |
Diluted Weighted Average Shares | 5037 | 5060 | 5060 | 5074 | 5068 |
Diluted EPS Excluding Extraordinary Items | 0.21302 | 0.27569 | 0.23083 | 0.14762 | 0.35556 |
Dividends per Share - Common Stock Primary Issue | 0.19 | 0.19 | 0.19 | 0.23 | 0.14 |
Diluted Normalized EPS | 0.19873 | 0.25375 | 0.3419 | 0.22566 | 0.2717 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 16711 | 15907 | 16927 | 19491 | 20247 | 18674 |
Cash and Short Term Investments | 4986 | 3911 | 3958 | 4786 | 6370 | 4335 |
Cash | 1462 | 826 | 569 | 795 | 1762 | 1427 |
Short Term Investments | 3524 | 3085 | 3389 | 3991 | 4608 | 2908 |
Total Receivables, Net | 5917 | 5950 | 6322 | 7148 | 7264 | 8031 |
Accounts Receivable - Trade, Net | 4679 | 4693 | 5185 | 5494 | 5562 | 6258 |
Total Inventory | 5102 | 5557 | 5476 | 5947 | 5996 | 5783 |
Prepaid Expenses | 335 | 308 | 330 | 316 | 359 | 315 |
Other Current Assets, Total | 371 | 181 | 841 | 1294 | 258 | 210 |
Total Assets | 59081 | 56381 | 58066 | 79692 | 80431 | 79103 |
Property/Plant/Equipment, Total - Net | 10808 | 10860 | 11058 | 11314 | 11006 | 10672 |
Property/Plant/Equipment, Total - Gross | 22164 | 21719 | 22488 | 22565 | 22313 | 21518 |
Accumulated Depreciation, Total | -11356 | -10859 | -11430 | -11251 | -11307 | -10846 |
Goodwill, Net | 5965 | 5734 | 5789 | 10562 | 10597 | 10552 |
Intangibles, Net | 18776 | 17562 | 17202 | 30955 | 29824 | 30079 |
Long Term Investments | 1248 | 1101 | 1558 | 2151 | 3424 | 2214 |
Note Receivable - Long Term | 886 | 875 | 816 | 893 | 858 | 935 |
Other Long Term Assets, Total | 4687 | 4342 | 4716 | 4326 | 4475 | 5977 |
Total Current Liabilities | 19001 | 26569 | 22491 | 24050 | 22148 | 23670 |
Accounts Payable | 3596 | 3528 | 3645 | 4144 | 4357 | 4535 |
Accrued Expenses | 6444 | 6929 | 8535 | 9111 | 9753 | 11186 |
Notes Payable/Short Term Debt | 1426 | 765 | 4420 | 5020 | 1145 | 802 |
Current Port. of LT Debt/Capital Leases | 2703 | 2060 | 1373 | 1898 | 2580 | 2799 |
Other Current Liabilities, Total | 4832 | 13287 | 4518 | 3877 | 4313 | 4348 |
Total Liabilities | 57957 | 56449 | 53706 | 68287 | 65844 | 64048 |
Total Long Term Debt | 14661 | 14264 | 20271 | 23590 | 23425 | 20572 |
Long Term Debt | 14620 | 14221 | 20227 | 22580 | 22538 | 19760 |
Capital Lease Obligations | 41 | 43 | 44 | 1010 | 887 | 812 |
Deferred Income Tax | 1934 | 1396 | 1156 | 3810 | 3600 | 3556 |
Minority Interest | 3839 | 3557 | -688 | 6952 | 6221 | 6287 |
Other Liabilities, Total | 18522 | 10663 | 10476 | 9885 | 10450 | 9963 |
Total Equity | 1124 | -68 | 4360 | 11405 | 14587 | 15055 |
Common Stock | 1342 | 1343 | 1345 | 1346 | 1346 | 1347 |
Additional Paid-In Capital | 2954 | 3019 | 3091 | 3174 | 3281 | 3301 |
Retained Earnings (Accumulated Deficit) | -3263 | -4348 | -8 | 6659 | 8884 | 10073 |
ESOP Debt Guarantee | -286 | -400 | -161 | -135 | -195 | -28 |
Unrealized Gain (Loss) | 380 | 329 | 140 | 409 | 1302 | 383 |
Other Equity, Total | -3 | -11 | -47 | -48 | -31 | -21 |
Total Liabilities & Shareholders’ Equity | 59081 | 56381 | 58066 | 79692 | 80431 | 79103 |
Total Common Shares Outstanding | 4910.11 | 4957.95 | 4922.93 | 4953.23 | 5029.98 | 5031.81 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 18524 | 17566 | 18254 | 18674 | 28988 |
Cash and Short Term Investments | 4817 | 3562 | 3514 | 4335 | 13977 |
Cash & Equivalents | 4757 | 3503 | 3453 | 4274 | 10967 |
Short Term Investments | 60 | 59 | 61 | 61 | 3010 |
Total Receivables, Net | 7183 | 7507 | 8284 | 8346 | 8797 |
Accounts Receivable - Trade, Net | 6492 | 6902 | 7697 | 7860 | 8300 |
Total Inventory | 6216 | 6330 | 6244 | 5783 | 6003 |
Other Current Assets, Total | 308 | 167 | 212 | 210 | 211 |
Total Assets | 78079 | 77011 | 78689 | 79103 | 89689 |
Property/Plant/Equipment, Total - Net | 10633 | 10589 | 10667 | 10672 | 10704 |
Goodwill, Net | 10442 | 10435 | 10582 | 10552 | 10705 |
Intangibles, Net | 29418 | 29333 | 30241 | 30079 | 30468 |
Long Term Investments | 3755 | 3235 | 2818 | 2214 | 1739 |
Other Long Term Assets, Total | 5307 | 5853 | 6127 | 6912 | 7085 |
Total Current Liabilities | 20275 | 21387 | 22417 | 23670 | 24278 |
Payable/Accrued | 14610 | 14267 | 15230 | 17554 | 17577 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 3172 | 5041 | 4869 | 3601 | 4102 |
Other Current Liabilities, Total | 2493 | 2079 | 2318 | 2515 | 2599 |
Total Liabilities | 63214 | 61634 | 63263 | 64048 | 73508 |
Total Long Term Debt | 23047 | 20442 | 20736 | 20572 | 29226 |
Long Term Debt | 23047 | 20442 | 20736 | 20572 | 29226 |
Deferred Income Tax | 3566 | 3587 | 3666 | 3556 | 3668 |
Minority Interest | 6145 | 6201 | 6322 | 6287 | 6451 |
Other Liabilities, Total | 10181 | 10017 | 10122 | 9963 | 9885 |
Total Equity | 14865 | 15377 | 15426 | 15055 | 16181 |
Common Stock | 1346 | 1347 | 1347 | 1347 | 1347 |
Additional Paid-In Capital | 3296 | 3299 | 3300 | 3301 | 3436 |
Retained Earnings (Accumulated Deficit) | 10223 | 10731 | 10779 | 10407 | 11398 |
Total Liabilities & Shareholders’ Equity | 78079 | 77011 | 78689 | 79103 | 89689 |
Total Common Shares Outstanding | 5031.39 | 5031.68 | 5031.74 | 5031.81 | 5083.9 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 1062 | 2169 | 4046 | 5268 | 6388 | 5096 |
Cash From Operating Activities | 6497 | 6918 | 8421 | 8020 | 8441 | 7952 |
Cash From Operating Activities | 978 | 988 | 954 | 1231 | 1214 | 1195 |
Amortization | 796 | 934 | 902 | 1103 | 1137 | 1182 |
Non-Cash Items | 1641 | 3072 | 1406 | 2416 | -305 | 1381 |
Cash Taxes Paid | 1609 | 1340 | 1326 | 1512 | 1655 | 1291 |
Cash Interest Paid | 732 | 781 | 766 | 895 | 864 | 786 |
Changes in Working Capital | 2020 | -245 | 1113 | -1998 | 7 | -902 |
Cash From Investing Activities | -1269 | -1443 | -1553 | -5354 | 2161 | -1777 |
Capital Expenditures | -2352 | -2202 | -1796 | -2163 | -2239 | -2931 |
Other Investing Cash Flow Items, Total | 1083 | 759 | 243 | -3191 | 4400 | 1154 |
Cash From Financing Activities | -6392 | -6380 | -6389 | -1840 | -10132 | -7589 |
Financing Cash Flow Items | -1687 | -1475 | -10660 | -1453 | -1950 | -1401 |
Total Cash Dividends Paid | -4850 | -3906 | -3927 | -3953 | -3977 | -3999 |
Issuance (Retirement) of Stock, Net | 15 | -9 | 74 | 51 | 29 | 21 |
Issuance (Retirement) of Debt, Net | 130 | -990 | 8124 | 3515 | -4234 | -2210 |
Foreign Exchange Effects | 283 | -100 | 8 | -82 | -39 | -29 |
Net Change in Cash | -881 | -1005 | 487 | 744 | 431 | -1443 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1260 | 2798 | 4166 | 5096 | 2167 |
Cash From Operating Activities | 331 | 1623 | 4185 | 7952 | 2542 |
Cash From Operating Activities | 361 | 1025 | 2011 | 2377 | 704 |
Non-Cash Items | 433 | 570 | 1140 | 1381 | 634 |
Cash Taxes Paid | 155 | 700 | 857 | 1291 | 213 |
Cash Interest Paid | 95 | 439 | 486 | 786 | 85 |
Changes in Working Capital | -1723 | -2770 | -3132 | -902 | -963 |
Cash From Investing Activities | -48 | -233 | -1416 | -1777 | -3593 |
Capital Expenditures | -354 | -1015 | -2299 | -2931 | -601 |
Other Investing Cash Flow Items, Total | 306 | 782 | 883 | 1154 | -2992 |
Cash From Financing Activities | -1376 | -3421 | -4815 | -7589 | 7973 |
Financing Cash Flow Items | -391 | -883 | -1052 | -1401 | 16 |
Total Cash Dividends Paid | -946 | -2097 | -3048 | -3999 | -952 |
Issuance (Retirement) of Stock, Net | 15 | 19 | 20 | 21 | 12 |
Issuance (Retirement) of Debt, Net | -54 | -460 | -735 | -2210 | 8897 |
Foreign Exchange Effects | -35 | -34 | -21 | -29 | 12 |
Net Change in Cash | -1128 | -2065 | -2067 | -1443 | 6934 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.5959 | 229134683 | -34164923 | 2022-07-19 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.1513 | 129037070 | 1316706 | 2022-11-29 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.3261 | 95245653 | 977516 | 2023-01-01 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 1.9416 | 79502299 | 0 | 2022-02-27 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.2735 | 52145714 | 113556 | 2023-01-01 | LOW |
Silchester International Investors, L.L.P. | Investment Advisor/Hedge Fund | 1.2688 | 51954188 | 12827890 | 2022-11-28 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.2106 | 49570121 | -418206 | 2023-01-01 | LOW |
Columbia Threadneedle Investments (UK) | Investment Advisor/Hedge Fund | 0.9197 | 37659407 | -1831852 | 2022-11-28 | LOW |
Schroder Investment Management Ltd. (SIM) | Investment Advisor/Hedge Fund | 0.8804 | 36048753 | 1255452 | 2023-01-01 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8357 | 34220716 | -131359 | 2023-01-01 | LOW |
Franklin Mutual Advisers, LLC | Investment Advisor/Hedge Fund | 0.7629 | 31239940 | 2050203 | 2023-01-01 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5453 | 22328352 | 526606 | 2022-11-29 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.5138 | 21037527 | -869474 | 2022-11-28 | LOW |
Jupiter Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.4996 | 20457122 | 1270578 | 2022-11-28 | LOW |
Independent Franchise Partners LLP | Investment Advisor | 0.4732 | 19376797 | 6500373 | 2022-11-29 | LOW |
Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.4639 | 18995200 | -674014 | 2023-01-01 | LOW |
GlaxoSmithKline Plc ESOP | Corporation | 0.4534 | 18564231 | -20616012 | 2021-12-31 | LOW |
Capital Research Global Investors | Investment Advisor | 0.4354 | 17828669 | -58801534 | 2022-11-29 | LOW |
Mondrian Investment Partners Ltd. | Investment Advisor | 0.4144 | 16967070 | -246648 | 2022-11-29 | LOW |
Schweizerische Nationalbank | Bank and Trust | 0.4129 | 16908425 | -1156909 | 2022-11-28 | LOW |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group +500000+
Trader
93000+
Klien aktif per bulan
$57000000+
Volume investasi per bulan
$31000000+
Coba sekarang Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Industry: | Pharmaceuticals (NEC) |
980 Great West Road
BRENTFORD
MIDDLESEX TW8 9GS
GB
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com